|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-11-10
|
|
pubmed:abstractText |
To evaluate the risk/benefit profiles of gefitinib in comparison with platinum-based doublets chemotherapy as a first-line treatment for chemonaïve patients with advanced non-small-cell lung cancer in East Asia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
242-52
|
|
pubmed:meshHeading |
pubmed-meshheading:18423782-Antineoplastic Agents,
pubmed-meshheading:18423782-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18423782-Clinical Trials, Phase II as Topic,
pubmed-meshheading:18423782-Clinical Trials, Phase III as Topic,
pubmed-meshheading:18423782-Far East,
pubmed-meshheading:18423782-Female,
pubmed-meshheading:18423782-Humans,
pubmed-meshheading:18423782-Lung Neoplasms,
pubmed-meshheading:18423782-Male,
pubmed-meshheading:18423782-Platinum Compounds,
pubmed-meshheading:18423782-Quinazolines
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.
|
|
pubmed:affiliation |
Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
